Crohn's disease complicated by strictures: A systematic review

Gut

Volumn 62, Issue 7, 2013, Pages 1072-1084

  Rieder, Florian ^a   Zimmermann, Ellen M ^b   Remzi, Feza H ^a   Sandborn, William J ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PLACEBO; STEROID; TRIAMCINOLONE;

ABDOMINAL PAIN; ABSCESS; ANASTOMOSIS LEAKAGE; BALLOON DILATATION; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; ENDOSCOPIC THERAPY; EPIDEMIOLOGICAL DATA; FEVER; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; INTESTINAL BLEEDING; INTESTINE FISTULA; INTESTINE PERFORATION; INTESTINE STENOSIS; INTESTINE SURGERY; MOLECULAR PATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEPSIS; SURGICAL APPROACH; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CROHN'S COLITIS; FIBROGENESIS; FIBROSIS; IBD CLINICAL;

CONSTRICTION, PATHOLOGIC; CROHN DISEASE; FIBROSIS; HUMANS; INTESTINES; RISK FACTORS;

EID: 84878759525     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-304353     Document Type: Review

References (164)

1. Pucilowska JB, Williams KL, Lund PK, et al. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Cell Physiol 2000;279:G653-9.
2. Burke JP, Mulsow JJ, O 'Keane C, et al. Fibrogenesis in Crohn's disease. Am J Gastroenterol 2007; 102:439-48. (Pubitemid 46160558)
3. Rieder F, Fiocchi C. Intestinal fibrosis in IBD - a dynamic, multifactorial process. Nat Rev 2009;6:228-35.
4. Speca S, Giusti I, Rieder F, et al. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol 2013;18:3635-61.
5. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996;110:975-84. (Pubitemid 26113734)
6. Vallance BA, Gunawan MI, Hewlett B, et al. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol 2005;289:G116-28. (Pubitemid 40944230)
7. Pucilowska JB, McNaughton KK, Mohapatra NK, et al. IGF-I and procollagen alpha1(I) are coexpressed in a subset of mesenchymal cells in active Crohn's disease. Am J Physiol 2000;279:G1307-22.
8. Mahavadi S, Flynn RS, Grider JR, et al. Amelioration of excess collagen IalphaI, fibrosis, and smooth muscle growth in TNBS-induced colitis in IGF-I(+/-) mice. Inflamm Bowel Dis 2011;17:711-19.
9. Lawrance IC, Maxwell L, Doe W. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis 2001;7:226-36. (Pubitemid 32776516)
10. Kumagai S, Ohtani H, Nagai T, et al. Platelet-derived growth factor and its receptors are expressed in areas of both active inflammation and active fibrosis in inflammatory bowel disease. Tohoku J Exp Med 2001;195:21-33. (Pubitemid 34036883)
11. Fichtner-Feigl S, Young CA, Kitani A, et al. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 2008;135:2003-13; 13 e1-7.
12. Zhu MY, Lu YM, Ou YX, et al. Dynamic progress of 2,4,6-trinitrobenzene sulfonic acid induced chronic colitis and fibrosis in rat model. J Dig Dis 2012;13:421-9.
13. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18:1028-40.
14. McKaig BC, McWilliams D, Watson SA, et al. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 2003;162:1355-60. (Pubitemid 36350679)
15. Lawrance IC, Wu F, Leite AZ, et al. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology 2003;125:1750-61. (Pubitemid 37500440)
16. Medina C, Santos-Martinez MJ, Santana A, et al. Transforming growth factor-beta type 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis. J Pathol 2011;224:461-72.
17. Rieder F, Georgieva M, Schirbel A, et al. Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts. Inflamm Bowel Dis 2010; 16:1505-13.
18. Flier SN, Tanjore H, Kokkotou EG, et al. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem 2010;285:20202-12.
19. Rieder F, Kessler SP, West GA, et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol 2012;179:2660-73.
20. Uehara H, Nakagawa T, Katsuno T, et al. Emergence of fibrocytes showing morphological changes in the inflamed colonic mucosa. Dig Dis Sci 2010;55:253-60.
21. Brittan M, Chance V, Elia G, et al. A regenerative role for bone marrow following experimental colitis: contribution to neovasculogenesis and myofibroblasts. Gastroenterology 2005;128:1984-95. (Pubitemid 40824707)
22. Rieder F, Bhilocha S, Schirbel A, et al. Activation of Toll-like receptor (TLR) 5 induces a pro-fibrogenic phenotype on human intestinal myofibroblasts (HIF) - a novel pathway mediated by caspase 1 (abstract). Gastroenterology 2011;142:S116.
23. Otte JM, Rosenberg IM, Podolsky DK. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 2003;124:1866-78. (Pubitemid 36666782)
24. Fichtner-Feigl S, Fuss IJ, Young CA, et al. Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol 2007;178:5859-70. (Pubitemid 46674383)
25. Kugathasan S, Saubermann LJ, Smith L, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007;56:1696-705. (Pubitemid 350206296)
26. Wells RG. The role of matrix stiffness in regulating cell behavior. Hepatology 2008;47:1394-400. (Pubitemid 351547925)
27. Adler J, Punglia DR, Dillman JR, et al. Computed tomography enterography findings correlate with tissue inflammation, not fibrosis in resected small bowel Crohn's disease. Inflamm Bowel Dis 2011;18:849-56.
28. Chiorean MV, Sandrasegaran K, Saxena R, et al. Correlation of CT enteroclysis with surgical pathology in Crohn's disease. Am J Gastroenterol 2007;102:2541-50. (Pubitemid 47631798)
29. Jacene HA, Ginsburg P, Kwon J, et al. Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med 2009;50:1751-9.
30. Zappa M, Stefanescu C, Cazals-Hatem D, et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn's disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis 2011;17:984-93.
31. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-82. (Pubitemid 33096034)
32. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010;139:1147-55.
33. Tarrant KM, Barclay ML, Frampton CM, et al. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008;103:3082-93.
34. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5:1430-8. (Pubitemid 350181602)
35. Wolters FL, Russel MG, Sijbrandij J, et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006;55:1124-30. (Pubitemid 44085679)
36. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50.
37. Agrez MV, Valente RM, Pierce W, et al. Surgical history of Crohn's disease in a well-de fined population. Mayo Clin Proc 1982;57:747-52. (Pubitemid 13221589)
38. Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease - based on results from a regional patient group from the county of Copenhagen. Gut 1985;26:146-50. (Pubitemid 15105140)
39. Wolters FL, Russel MG, Sijbrandij J, et al. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol Suppl 2006:46-54. (Pubitemid 43941066)
40. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985;88:1818-25. (Pubitemid 15052293)
41. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010;105:289-97.
42. Ramadas AV, Gunesh S, Thomas GA, et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59:1200-6.
43. Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early postoperative recurrence of Crohn's disease. Gastroenterology 1998;115:259-67. (Pubitemid 28363417)
44. Sachar DB, Subramani K, Mauer K, et al. Patterns of postoperative recurrence in fistulizing and stenotic Crohn's disease. A retrospective cohort study of 71 patients. J Clin Gastroenterol 1996; 22:114-16. (Pubitemid 26073296)
45. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(Suppl. A):5-36.
46. Oberhuber G, Stangl PC, Vogelsang H, et al. Significant association of strictures and internal fistula formation in Crohn's disease. Virchows Arch 2000;437:293-7.
47. Sheehan AL, Warren BF, Gear MW, et al. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg 1992;79:955-8.
48. Jurgens M, Brand S, Laubender RP, et al. The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn's disease independent of the IL23R genotype. J Gastroenterol 2010;45:721-31.
49. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
50. Fukumoto A, Tanaka S, Yamamoto H, et al. Diagnosis and treatment of small-bowel stricture by double balloon endoscopy. Gastrointest Endosc 2007;66:S108-12. (Pubitemid 47263462)
51. Freeman HJ. Natural history and clinical behavior of Crohn's disease extending beyond two decades. J Clin Gastroenterol 2003;37:216-19. (Pubitemid 37010915)
52. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology 2007;133:1670-89. (Pubitemid 350029755)
53. Goldberg HI, Caruthers SB Jr, Nelson JA, et al. Radiographic findings of the National Cooperative Crohn's Disease Study. Gastroenterology 1979;77:925-37. (Pubitemid 9242055)
54. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665-72. (Pubitemid 14122134)
55. Rieder F, Lawrance IC, Leite A, et al. Predictors of fibrostenotic Crohn's disease. Inflamm Bowel Dis 2011;17:2000-7.
56. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008;43:948-54.
57. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006;130:650-6. (Pubitemid 43374514)
58. Lakatos PL, Czegledi Z, Szamosi T, et al. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn' s disease. World J Gastroenterol 2009;15:3504-10.
59. Unkart JT, Anderson L, Li E, et al. Risk factors for surgical recurrence after ileocolic resection of Crohn's disease. Dis Colon Rectum 2008;51:1211-16.
60. Louis E, Michel V, Hugot JP, et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003;52:552-7. (Pubitemid 36363410)
61. Allez M, Lemann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol 2010;16:2626-32.
62. Adler J, Rangwalla SC, Dwamena BA, et al. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol 2011;106:699-712.
63. Alvarez-Lobos M, Arostegui JI, Sans M, et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005;242:693-700. (Pubitemid 41567125)
64. Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, et al. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol 2007;13:2960-6. (Pubitemid 47028884)
65. Henckaerts L, Pierik M, Joossens M, et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 2007;56:1536-42. (Pubitemid 350033192)
66. Lakatos PL, Papp M, Rieder F. Serologic antiglycan antibodies in inflammatory bowel disease. Am J Gastroenterol 2010;106:406-12.
67. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008;6:1105-11.
68. Rieder F, Schleder S, Wolf A, et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis 2010;16:1367-75.
69. Rieder F, Lopez R, Franke A, et al. Characterization of changes in serum anti-glycan antibodies in Crohn's disease - a longitudinal analysis. PLoS One 2010;6:e18172.
70. Gasche C, Moser G, Turetschek K, et al. Transabdominal bowel sonography for the detection of intestinal complications in Crohn's disease. Gut 1999;44:112-17. (Pubitemid 29143290)
71. Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease. Inflamm Bowel Dis 2011;17:1073-80.
72. Voderholzer WA, Beinhoelzl J, Rogalla P, et al. Small bowel involvement in Crohn's disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. Gut 2005;54:369-73. (Pubitemid 40299093)
73. Huprich JE, Fletcher JG. CT enterography: principles, technique and utility in Crohn's disease. Eur J Radiol 2009;69:393-7.
74. Kambadakone AR, Chaudhary NA, Desai GS, et al. Low-dose MDCT and CT enterography of patients with Crohn disease: feasibility of adaptive statistical iterative reconstruction. AJR Am J Roentgenol 2011;196:W743-52.
75. Kroeker KI, Lam S, Birchall I, et al. Patients with IBD are exposed to high levels of ionizing radiation through CT scan diagnostic imaging: a five-year study. J Clin Gastroenterol 2011;45:34-9.
76. Maglinte DD, Bender GN, Heitkamp DE, et al. Multidetector-row helical CT enteroclysis. Radiol Clin North Am 2003;41:249-62. (Pubitemid 36351095)
77. Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc 2008;68:255-66. (Pubitemid 352024383)
78. Turetschek K, Schober E, Wunderbaldinger P, et al. Findings at helical CT-enteroclysis in symptomatic patients with crohn disease: correlation with endoscopic and surgical findings. J Comput Assist Tomogr 2002;26:488-92.
79. Vogel J, da Luz Moreira A, Baker M, et al. CT enterography for Crohn's disease: accurate preoperative diagnostic imaging. Dis Colon Rectum 2007;50:1761-9. (Pubitemid 350077091)
80. Bruining DH, Siddiki HA, Fletcher JG, et al. Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence. Inflamm Bowel Dis 2012;18:219-25.
81. Pilleul F, Godefroy C, Yzebe-Beziat D, et al. Magnetic resonance imaging in Crohn's disease. Gastroenterol Clin Biol 2005; 29:803-8. (Pubitemid 41411360)
82. Tillack C, Seiderer J, Brand S, et al. Correlation of magnetic resonance enteroclysis (MRE) and wireless capsule endoscopy (CE) in the diagnosis of small bowel lesions in Crohn's disease. Inflamm Bowel Dis 2008;14:1219-28.
83. Florie J, Horsthuis K, Hommes DW, et al. Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease. Clin Gastroenterol Hepatol 2005;3:1221-8.
84. van Gemert-Horsthuis K, Florie J, Hommes DW, et al. Feasibility of evaluating Crohn's disease activity at 3.0 Tesla. J Magn Reson Imaging 2006;24:340-8.
85. Maccioni F, Bruni A, Viscido A, et al. MR imaging in patients with Crohn disease: value of T2- versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent. Radiology 2006;238:517-30. (Pubitemid 43134364)
86. Magnano G, Granata C, Barabino A, et al. Polyethylene glycol and contrast-enhanced MRI of Crohn's disease in children: preliminary experience. Pediatr Radiol 2003;33:385-91. (Pubitemid 36748391)
87. Negaard A, Paulsen V, Sandvik L, et al. A prospective randomized comparison between two MRI studies of the small bowel in Crohn's disease, the oral contrast method and MR enteroclysis. Eur Radiol 2007;17:2294-301. (Pubitemid 47288266)
88. Sinha R, Verma R, Verma S, et al. MR enterography of Crohn disease: part 2, imaging and pathologic findings. AJR Am J Roentgenol 2011;197:80-5.
89. Sinha R, Verma R, Verma S, et al. MR enterography of Crohn disease: part 1, rationale, technique, and pitfalls. AJR Am J Roentgenol 2011;197:76-9.
90. Lawrance IC, Welman CJ, Shipman P, et al. Correlation of MRI-determined small bowel Crohn's disease categories with medical response and surgical pathology. World J Gastroenterol 2009;15:3367-75.
91. Jensen MD, Ormstrup T, Vagn-Hansen C, et al. Interobserver and intermodality agreement for detection of small bowel Crohn's disease with MR enterography and CT enterography. Inflamm Bowel Dis 2011;17:1081-8.
92. Van Assche G, Herrmann KA, Louis E, et al. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. J Crohn's Colitis Published Online First: 11 Feb 2013. pii: 51873-9946(13)0031-7.
93. Bruining DH, Loftus EV Jr, Ehman EC, et al. Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011;9:679-83; e1.
94. Adler J, Swanson SD, Schmiedlin-Ren P, et al. Magnetization transfer helps detect intestinal fibrosis in an animal model of Crohn disease. Radiology 2012;259:127-35.
95. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011;17:1415-22.
96. Lenze F, Wessling J, Bremer J, et al. Detection and differentiation of inflammatory versus fibromatous Crohn's disease strictures: prospective comparison of 18F-FDG-PET/CT, MR-enteroclysis, and transabdominal ultrasound versus endoscopic/histologic evaluation. Infl amm Bowel Dis 2012; 18:2252-60.
97. Stidham RW, Xu J, Johnson LA, et al. Ultrasound elasticity imaging for detecting intestinal fibrosis and inflammation in rats and humans with Crohn's disease. Gastroenterology 2011;141:819-26; e1.
98. Armuzzi A, Van Assche G, Reinisch W, et al. Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. J Crohn's Colitis 2012;6:492-502.
99. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-41. (Pubitemid 40139240)
100. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008;135:1493-9.
101. Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011;60:930-6.
102. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7. (Pubitemid 351284485)
103. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
104. Yaffe BH, Korelitz BI. Prognosis for nonoperative management of small-bowel obstruction in Crohn's disease. J Clin Gastroenterol 1983;5:211-15. (Pubitemid 13097022)
105. Vasilopoulos S, Kugathasan S, Saeian K, et al. Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn's disease. Am J Gastroenterol 2000;95:2503.
106. Toy LS, Scherl EJ, Kornbluth A, et al. Complete bowel obstruction following initial response to infliximab therapy for Crohn's disease: a series of a newly described complication. Gastroenterology 2000;118:A569.
107. Pallotta N, Barberani F, Hassan NA, et al. Effect of infliximab on small bowel stenoses in patients with Crohn's disease. World J Gastroenterol 2008;14:1885-90. (Pubitemid 351523819)
108. Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006;101:1030-8. (Pubitemid 43725317)
109. Sorrentino D. Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far? Digestion 2008;77:38-47. (Pubitemid 351552977)
110. Froehlich F, Juillerat P, Pittet V, et al. Maintenance of surgically induced remission of Crohn's disease. Digestion 2007;76:130-5. (Pubitemid 351194907)
111. Hassan C, Zullo A, De Francesco V, et al. Systematic review: endoscopic dilatation in Crohn's disease. Aliment Pharmacol Ther 2007;26:1457-64. (Pubitemid 350178804)
112. Gustavsson A, Magnuson A, Blomberg B, et al. Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn's disease. Aliment Pharmacol Ther 2012;36:151-8.
113. Thienpont C, D'Hoore A, Vermeire S, et al. Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut 2010;59:320-4.
114. Scimeca D, Mocciaro F, Cottone M, et al. Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn's disease strictures. Dig Liver Dis 2011;43:121-5.
115. Couckuyt H, Gevers AM, Coremans G, et al. Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: a prospective longterm analysis. Gut 1995;36:577-80.
116. Hoffmann JC, Heller F, Faiss S, et al. Through the endoscope balloon dilation of ileocolonic strictures: prognostic factors, complications, and effectiveness. Int J Colorectal Dis 2008;23:689-96.
117. Thomas-Gibson S, Brooker JC, Hayward CM, et al. Colonoscopic balloon dilation of Crohn's strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol 2003;15:485-8. (Pubitemid 36571039)
118. Solem CA, Harmsen WS, Zinsmeister AR, et al. Small intestinal adenocarcinoma in Crohn's disease: a case-control study. Infl amm Bowel Dis 2004;10:32-5. (Pubitemid 38072443)
119. Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 2001;120:820-6. (Pubitemid 32193178)
120. Yamazaki Y, Ribeiro MB, Sachar DB, et al. Malignant colorectal strictures in Crohn's disease. Am J Gastroenterol 1991;86:882-5.
121. Kornbluth A. Endoscopic management of intestinal strictures in Crohn's disease: commentary. Inflamm Bowel Dis 2007;13:362-63. (Pubitemid 46465918)
122. Despott EJ, Gupta A, Burling D, et al. Effective dilation of small-bowel strictures by double-balloon enteroscopy in patients with symptomatic Crohn's disease (with video). Gastrointest Endosc 2009;70:1030-6.
123. Hirai F, Beppu T, Sou S, et al. Endoscopic balloon dilatation using double-balloon endoscopy is a useful and safe treatment for small intestinal strictures in Crohn's disease. Dig Endosc 2010;22:200-4.
124. Di Nardo G, Oliva S, Passariello M, et al. Intralesional steroid injection after endoscopic balloon dilation in pediatric Crohn's disease with stricture: a prospective, randomized, double-blind, controlled trial. Gastrointest Endosc 2010;72:1201-8.
125. Singh VV, Draganov P, Valentine J. Efficacy and safety of endoscopic balloon dilation of symptomatic upper and lower gastrointestinal Crohn's disease strictures. J Clin Gastroenterol 2005;39:284-90. (Pubitemid 40393242)
126. Ramage JI Jr, Rumalla A, Baron TH, et al. A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures. Am J Gastroenterol 2005;100:2419-25.
127. Nelson RS, Hernandez AJ, Goldstein HM, et al. Treatment of irradiation esophagitis. Value of hydrocortisone injection. Am J Gastroenterol 1979;71:17-23. (Pubitemid 9147442)
128. Kochhar R, Poornachandra KS. Intralesional steroid injection therapy in the management of resistant gastrointestinal strictures. World J Gastrointest Endosc 2010;2:61-8.
129. Kochhar R, Makharia GK. Usefulness of intralesional triamcinolone in treatment of benign esophageal strictures. Gastrointest Endosc 2002;56:829-34. (Pubitemid 36236711)
130. Roques C, Teot L. The use of corticosteroids to treat keloids: a review. Int J Low Extrem Wounds 2008;7:137-45.
131. Ramboer C, Verhamme M, Dhondt E, et al. Endoscopic treatment of stenosis in recurrent Crohn' s disease with balloon dilation combined with local corticosteroid injection. Gastrointest Endosc 1995;42:252-5.
132. Brooker JC, Beckett CG, Saunders BP, et al. Long-acting steroid injection after endoscopic dilation of anastomotic Crohn's strictures may improve the outcome: a retrospective case series. Endoscopy 2003;35:333-7.
133. East JE, Brooker JC, Rutter MD, et al. A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of Crohn's strictures. Clin Gastroenterol Hepatol 2007;5:1065-9.
134. Swaminath A, Lichtiger S. Dilation of colonic strictures by intralesional injection of in fliximab in patients with Crohn's colitis. Inflamm Bowel Dis 2008;14:213-16. (Pubitemid 351288042)
135. Sorrentino D, Avellini C, Beltrami CA, et al. Selective effect of in fliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis 2006;21:276-81. (Pubitemid 43280336)
136. Levine RA, Wasvary H, Kadro O. Endoprosthetic management of refractory ileocolonic anastomotic strictures after resection for Crohn's disease: report of nine-year follow-up and review of the literature. In flamm Bowel Dis 2012;18:506-12.
137. Attar A, Maunoury V, Vahedi K, et al. Safety and efficacy of extractible self-expandable metal stents in the treatment of Crohn's disease intestinal strictures: a prospective pilot study. Inflamm Bowel Dis 2012;18:1849-54.
138. Branche J, Attar A, Vernier-Massouille G, et al. Extractible self-expandable metal stent in the treatment of Crohn's disease anastomotic strictures. Endoscopy 2012;44 (Suppl. 2) UCTN:E325-6.
139. Rejchrt S, Kopacova M, Brozik J, et al. Biodegradable stents for the treatment of benign stenoses of the small and large intestines. Endoscopy 2011;43:911-17.
140. Toth E, Nielsen J, Nemeth A, et al. Treatment of a benign colorectal anastomotic stricture with a biodegradable stent. Endoscopy 2011; 43(Suppl. 2) UCTN:E252-3.
141. Bedogni G, Ricci E, Pedrazzoli C, et al. Endoscopic dilation of anastomotic colonic stenosis by different techniques: an alternative to surgery? Gastrointest Endosc 1987;33:21-4. (Pubitemid 17010105)
142. Lavy A. Triamcinolone improves outcome in Crohn's disease strictures. Dis Colon Rectum 1997;40:184-6. (Pubitemid 27074289)
143. Raedler A, Peters I, Schreiberg S. Treatment with azathioprin and budesonide prevents reoccurence of ileocolonic stenoses after endoscopic dilatation in Crohn's disease. Gastroenterology 1997;112:A1067.
144. Heuman R, Boeryd B, Bolin T, et al. The influence of disease at the margin of resection on the outcome of Crohn's disease. Br J Surg 1983;70:519-21. (Pubitemid 13001790)
145. Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn's disease in the small bowel. A randomized controlled trial. Ann Surg 1996;224:563-71; discussion 71-3.
146. McLeod RS, Wolff BG, Ross S, et al. Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Dis Colon Rectum 2009;52:919-27.
147. Alexander-Williams J. The technique of intestinal strictureplasty. Int J Colorectal Dis 1986;1:54-7. (Pubitemid 18002895)
148. Hurst RD, Michelassi F. Strictureplasty for Crohn's disease: techniques and long-term results. World J Surg 1998;22:359-63. (Pubitemid 28113522)
149. Michelassi F. Side-to-side isoperistaltic strictureplasty for multiple Crohn's strictures. Dis Colon Rectum 1996;39:345-9. (Pubitemid 26091343)
150. Roy P, Kumar D. Strictureplasty. Br J Surg 2004;91:1428-37. (Pubitemid 39518077)
151. Jobanputra S, Weiss EG. Strictureplasty. Clin Colon Rectal Surg 2007;20:294-302.
152. Ambe R, Campbell L, Cagir B. A comprehensive review of strictureplasty techniques in Crohn's disease: types, indications, comparisons, and safety. J Gastrointest Surg 2012;16:209-17.
153. Wibmer AG, Kroesen AJ, Grone J, et al. Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn's disease - review of the literature. Int J Colorectal Dis 2010;25:1149-57.
154. Dietz DW, Laureti S, Strong SA, et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn's disease. J Am Coll Surg 2001;192:330-7; discussion 7-8.
155. Baba S, Nakai K. Strictureplasty for Crohn's disease in Japan. J Gastroenterol 1995;30(Suppl. 8):135-8.
156. Tichansky D, Cagir B, Yoo E, et al. Strictureplasty for Crohn's disease: meta-analysis. Dis Colon Rectum 2000;43:911-19. (Pubitemid 30464059)
157. Fichera A, Lovadina S, Rubin M, et al. Patterns and operative treatment of recurrent Crohn's disease: a prospective longitudinal study. Surgery 2006;140:649-54. (Pubitemid 44442344)
158. Reese GE, Purkayastha S, Tilney HS, et al. Strictureplasty vs resection in small bowel Crohn's disease: an evaluation of short-term outcomes and recurrence. Colorectal Dis 2007;9:686-94. (Pubitemid 47422966)
159. Roy P, Kumar D. Strictureplasty for active Crohn's disease. Int J Colorectal Dis 2006;21:427-32.
160. Partridge SK, Hodin RA. Small bowel adenocarcinoma at a strictureplasty site in a patient with Crohn's disease: report of a case. Dis Colon Rectum 2004;47:778-81. (Pubitemid 38585786)
161. Marchetti F, Fazio VW, Ozuner G. Adenocarcinoma arising from a strictureplasty site in Crohn's disease. Report of a case. Dis Colon Rectum 1996;39:1315-21. (Pubitemid 26389547)
162. Broering DC, Eisenberger CF, Koch A, et al. Strictureplasty for large bowel stenosis in Crohn's disease: quality of life after surgical therapy. Int J Colorectal Dis 2001;16:81-7. (Pubitemid 32318341)
163. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease:
164. Felley C, Vader JP, Juillerat P, et al. Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: results of a multidisciplinary expert panel - EPACT II. J Crohn's Colitis 2009;3:250-6.